On October 2, 2020 Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, reported the pricing of an underwritten public offering of 3,225,806 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $3.10 per share (Press release, Benitec Biopharma, OCT 2, 2020, View Source [SID1234567994]). The Company expects to receive aggregate gross proceeds of approximately $10.0 million from the offering. The offering is expected to close on or about October 6, 2020, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The Company has also granted the underwriter a 30-day option to purchase up to 483,870 additional shares of its common stock, at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

The Company intends to use the net proceeds from the offering for the continued advancement of development activities for its product pipeline, general corporate purposes, and strategic growth opportunities.

A registration statement on Form S-1 (File No. 333-246314) relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on October 2, 2020. This offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus relating to the offering may be obtained for free by visiting the SEC’s website at www.sec.gov or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at 646-975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On October 2, 2020 Medscape reported that The International Association for the Study of Lung Cancer (IASLC) has selected Medscape Oncology as its partner to host and manage these IASLC virtual conferences in 2020 (Press release, Medscape, OCT 2, 2020, View Source [SID1234567992]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– IASLC 2020 Hot Topic Meeting: Liquid Biopsy: A worldwide virtual event scheduled for
October 2-3, 2020
– IASLC 2020 North America Conference on Lung Cancer (NACLC): A worldwide virtual event scheduled for October 16-17, 2020

In collaboration with the IASLC, Medscape Oncology and MedscapeLIVE! will offer an immersive and engaging conference learning environment reaching the members of the thoracic oncology community including physicians, nurses, other clinicians, researchers and scientists as well as patients, survivors and advocates in the field of lung cancer.

The two conferences will include interactive educational sessions, late-breaking research, live chats with industry and e-poster presenters, interactive breakout sessions, networking opportunities and Virtual Exhibit Halls with product theaters.

"We are pleased to partner with Medscape in the delivery of the IASLC’s remaining 2020 meetings. The MedscapeLIVE! virtual conference platform and production services allow us to accomplish our mission of using all available means to deliver quality education to eliminate lung cancer and other thoracic malignancies. This partnership allows us to share important information with a global audience through live stream and on-demand content—while allowing us to protect the health of our members and their respective communities," said Dave Mesko, IASLC Chief Executive Officer.

The IASLC’s Mission

To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.
"We are honored to partner with the IASLC to offer comprehensive and immersive virtual meetings. As we are during a time of great change, it is more important than ever that healthcare providers across the world have access to digital education that aids in their ability to stay current with the latest changes in their field. We are excited to be working with the IASLC to deliver this critical information and impact provider practices and patient care," said Rejéan Rochette, Group General Manager, Medscape Education.

To learn more about the IASLC’s upcoming meetings, visit View Source

About the International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association’s membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines in more than 100 countries.

By hosting global conferences, funding cutting-edge research and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families and communities.

Each year, the IASLC hosts the World Conference on Lung Cancer (WCLC), the world’s largest meeting dedicated solely to thoracic cancers. The WCLC attracts more than 7,500 lung cancer specialists from across the world and offers attendees networking opportunities while providing a podium for practice-changing research.

In keeping with their commitment to education, the IASLC publishes the Journal of Thoracic Oncology (JTO), a primary source for thoracic malignancy prevention, detection, diagnosis and treatment information. The JTO serves as an authoritative resource in the field, with its impact factor increased from 12.460 in 2018 to 13.357 in 2019. Additionally, at the beginning of 2020, the IASLC launched a gold open-access publication to accompany the JTO entitled JTO Clinical and Research Reports.

On October 2, 2020 BD (Becton, Dickinson and Company) (NYSE:BDX) reported that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday, November 5, 2020, at 8:00 a.m. (ET) (Press release, BD Pharmaceutical Systems, OCT 2, 2020, View Source [SID1234567991]). BD will issue a press release detailing the quarter’s earnings earlier that morning.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the conference call, along with related slides, will be accessible through BD’s website at www.bd.com/investors and will be available for replay through Thursday, November 12, 2020.

On October 2, 2020 Unum Group (NYSE: UNM) reported that it will release its third quarter 2020 results October 27, at approximately 4:15 p.m. Eastern time (Press release, Unum Therapeutics, OCT 2, 2020, https://www.prnewswire.com/news-releases/unum-group-to-release-third-quarter-2020-results-and-host-conference-call-301145053.html [SID1234567989]). The earnings release and financial supplement will be available in the Investors section of the company’s website, which can be directly accessed at www.investors.unum.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of Unum Group senior management will host a conference call Wednesday, October 28, at 8 a.m. Eastern time to discuss the results of operations for the third quarter. Topics may include forward-looking information, such as guidance on future results or trends in operations, as well as other material information. Interested parties are invited to listen and participate in the question-and-answer segment by dialing the appropriate number.

A live webcast of the call will be accessible from the Investors section of the company’s website in a listen-only mode. It is recommended that interested parties access the webcast approximately 5-10 minutes prior to the start of the call. The company will maintain a replay of the call on its website through Wednesday, November 4. Interested parties may access the replay by dialing the appropriate number.

On October 2, 2020 Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM), reported that it will release the financial results for its third quarter ended September 30, 2020 on Thursday, October 29, 2020 after the market closes (Press release, Select Medical, OCT 2, 2020, View Source [SID1234567988]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Select Medical will host a conference call regarding its third quarter results, as well as the impact of the COVID-19 pandemic on each of its reporting segments, on Friday, October 30, 2020, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 6297066. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation’s website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 11:00am ET, November 6, 2020. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 6297066. The replay can also be accessed at Select Medical Holdings Corporation’s website, www.selectmedicalholdings.com.